As per the two-year agreement, the companies will use technology developed at the Massachusetts Eye and Ear Infirmary in the Eaton-Peabody Laboratory by investigator and Audion co-founder Albert Edge.
Further, Audion could license technology rights to Sanofi in connection with the research conducted under the current deal.
Sanofi Global Research & Development president Elias Zerhouni said this collaboration is a multi-disciplinary approach with their internal Aging Therapeutic Strategic Unit and Early-to-Candidate Unit working together to advance novel therapies in the field of otolaryngology using advanced technologies available to study cochlear biology.